

ISSN 0975-413X CODEN (USA): PCHHAX

Der Pharma Chemica, 2016, 8(4):399-413 (http://derpharmachemica.com/archive.html)

New Potential Antitumor Nitrogen Heterocycles: Synthesis and Cytotoxic Evaluation

Elsherbiny H. Elsayed and Eman M. Radwan*

Chemistry Department, Faculty of Science, Port-Said University, 23 December Street, Port-Said 42521, Egypt

ABSTRACT

A new 2-(p-nitrobenzylidene)-4-phenyl-5-oxo(thioxo)-1,2,4-triazino-[2,1-a]-1,2,4-triazine-1,7-diones (2a,b) and 2-(5-phenylthiazol-2-yl)-3-phenyl-5-(p-nitrobenzylidene)-1,2,4-triazine-6-one (5) were prepared via cyclocondensation of 2-substituted-1,2,4-triazine (1a,b) with ethyl chloroacetate and phenacyl bromide in presence of fused sodium acetate. Alkylation of compounds 2a,b with ethyl chloroacetate in dimethyl formamide yielded Nalkylated products (3a,b). Condensation of compound 2a with aromatic aldehydes afforded the corresponding arylidene derivatives (4a,b). N-acetyl derivative (6) was obtained via acetylation of compound 5 with acetic anhydride. The structures of the compounds were elucidated by using spectral and elemental analysis. All the prepared fused triazino- and thiazolyl-1,2,4-triazine were evaluated for their cytotoxicity against HepG-2 cell line. Some of newly synthesized 1,2,4-triazine derivatives emerged as a potential candidate for the development of future cytotoxic compounds.

INTRODCUTION

Nitrogen and sulfur heterocycles have been under investigation for a long time because of their significant medicinal properties. 1,2,4-triazines and their derivatives have been widely studied in terms of their synthetic methodologies and reactivity since some of these derivatives were reported to have promising biological activities [1-4]. A survey of the literature revealed that 2,5-disubstituted-3,1-oxazolin-4-ones are the most common reagents used for the synthesis of 1,2,4-triazines and their derivatives [5-7]. 1,2,4-Triazine derivatives have been reported to possess a broad spectrum of biological activities, including antifungal [8,9], anti-HIV [10,12], anticancer [13,14], anti-inflammatory [15,16], analgesic [17] and antihypertensive activities [18]. Besides this, 1,2,4-triazines were used as herbicides, pesticides and dyes [19,20].

This prompted us to synthesize fused triazino derivatives of 1,2,4-triazines, thiazolyl derivatives of 1,2,4-triazines and evaluate them for antitumor activities.

MATERIALS AND METHODS

NMR spectra were recorded on a General Electric QE 300 instrument and chemical shifts were given with respect to TMS. IR spectra were recorded on a Perkin-Elmer 1420 spectrometer and a Broad FTS7 (KBr). Mass spectra were obtained on a Jeol JMS D-300 spectrometer operating at 70 eV. Microanalysis were conducted using an Elemental analyser 1106. Melting points were determined on a Reichet Hot Stage and uncorrected.

Synthesis of 5-(*p*-nitrobenzylidene)-3-phenyl-2-substituted-1,2,4-triazine-6-one (1a,b)

A mixture of 5-(p-nitrobenzylidene)-2-phenyl-3,1-oxazole-4-one (0.01 mole), semicarbazide hydrochloride and/or thiosemicarbazide (0.01 mole) and fused sodium acetate (0.03 mole) in glacial acetic acid (30 ml) was heated under reflux for 4 hr, then cooled and poured into water. The resulting solid was filtered off, washed with water, dried and purified with ethanol to give **1a,b**.

5-(*p*-Nitrobenzylidene)-3-phenyl-2-(aminocarbonyl)-1,2,4-triazine-6-one (**1a**) as yellow crystals, yield 71%, m.p. 265 °C. IR (KBr): 3414, 3217 (NH₂), 3267 (NH), 1730, 1714 (C=O), 1637 (C=N), 1597, 1516 (C=C) cm⁻¹. ¹H-NMR (DMSO-d₆): δ 6.50 (s, 2H, NH₂), 7.36-8.59 (m, 10H, Ar-H and H-olefinic), 9.05 (br. s, 1H, NH) ppm. ¹³C- NMR (DMSO-d₆): δ 169.45, 165.32 (C=O), 148.25, 147.90 (C=N), 140.87, 140.07, 139.49, 136.71, 134.76, 133.69, 133.29, 133.04, 129.89, 129.40, 129.30, 129.15, 128.87, 127.89, 127.44, 125.55, 125.28, 124.26 (C-aromatic, triazine and C-olefinic) ppm. MS: (m/z, %) = 352 (M⁺+1, 1.70), 351 (M⁺, 11.70), 350 (M⁺-1, 56.50), 335 (2.40), 334 (2.20), 320 (1.20), 319 (4.70), 309 (18.70), 308 (100), 294 (11.10), 293 (34.50), 291 (7.60), 263 (1.30), 262 (3.30), 261 (3.70), 247 (3.40), 246 (4.60), 245 (2.20), 236 (1.30), 233 (1.40), 232 (1.30), 218 (1.20), 217 (2.10), 205 (1.80), 204 (3.40), 203 (3.10), 176 (3.10), 175 (6.80), 162 (5.90), 161 (15.60), 151 (1.60), 150 (1.90), 149 (7.90), 147 (3.60), 132 (2.20), 131 (2.30), 129 (4.00), 120 (5.80), 119 (48.00), 117 (5.10), 106 (4.10), 105 (53.50), 104 (42.00), 103 (12.60), 101 (11.70), 91 (1.60), 90 (2.20), 89 (8.80), 78 (2.70), 77 (32.80), 76 (8.00), 75 (10.00), 52 (1.10), 51 (6.60). Anal. Calcd for C₁₇H₁₃N₅O₄ (351): C, 58.12; H, 3.70; N, 19.94. Found: C, 58.03; H, 3.58; N, 19.78.

5-(p-Nitrobenzylidene)-3-phenyl-2-(aminothiocarbonyl)-1,2,4-triazine-6-one (**1b**) as yellow crystals, yield 73%, m.p. 220 °C. IR (KBr): 3422, 3163 (NH₂), 3285 (NH), 1730 (C=O), 1637 (C=N), 1600, 1518 (C=C), 1492 (C=S), 1101 (C-O) cm⁻¹. ¹H-NMR (DMSO-d₆): δ 7.23–8.53 (m, 12H, Ar-H, H-olefinic and NH₂), 10.72 (s, 1H, NH), 11.71 (s, 1H, OH) ppm. ¹³C-NMR (DMSO-d₆): δ 184.97, 182.43 (C=S), 168.56 (C=O), 161.50 (C-O), 148.03, 141.19 (C=N), 140.80, 140.01, 139.33, 133.54, 133.35, 132.92, 132.62, 131.14, 130.29, 129.95, 129.43, 129.11, 129.02, 128.30, 128.16, 124.91, 124.49, 124.30 (C-aromatic, triazine and C-olefinic) ppm. MS (m/z, %) = 368 (M⁺+1, 6.50), 366 (M⁺-1, 1.00), 340 (1.10), 339 (1.20), 324 (1.10), 319 (1.30), 308 (11.20), 295 (7.00), 294 (21.80), 293 (18.30), 280 (1.20), 279 (1.00), 278 (1.20), 235 (1.10), 234 (1.20), 219 (1.30), 218 (1.80), 205 (1.40), 204 (1.20), 178 (1.10), 177 (1.10), 176 (1.00), 174 (1.40), 172 (1.80), 164 (1.40), 163 (2.80), 162 (3.90), 161 (2.20), 159 (1.30), 157 (1.30), 152 (1.10), 150 (2.40), 149 (1.70), 144 (2.00), 143 (1.40), 133 (1.30), 132 (3.10), 131 (1.90), 130 (2.30), 129 (2.40), 128 (2.00), 122 (6.40), 121 (14.60), 119 (3.40), 118 (3.50), 116 (6.30), 115 (7.10), 114 (3.60), 107 (2.70), 106 (27.60), 105 (100), 102 (5.60), 101 (2.40), 91 (4.10), 90 (4.00), 89 (10.10), 88 (4.60), 87 (2.20), 78 (13.10), 77 (100), 75 (8.10), 65 (3.00), 64 (2.60), 63 (7.50), 62 (4.50), 52 (4.10), 51 (30.80). Anal. Calcd for C₁₇H₁₃N₅O₃S (367): C, 55.58; H, 3.54; N, 19.07. Found: C, 55.39; H, 3.33; N, 18.98.

Synthesis of 2-(*p*-nitrobenzylidene)-4-phenyl-5-substituted-1,2,4-triazino-[2,1-*a*]-1,2,4-triazine-1,7-dione (2a,b) A mixture of 2-substituted-1,2,4-triazine-6-ones (1a,b, 0.01 mole), ethyl chloroacetate (0.01 mole) and fused sodium acetate (0.03 mole) in glacial acetic acid (30 ml) was heated under reflux for 4 hr. The reaction mixture was cooled and poured into ice-water. The resulting solid was filtered off, washed with water, dried and purified by suitable solvent to give 2a,b.

2-(*p*-Nitrobenzylidene)-4-phenyl-triazino-[2,1-a]-1,2,4-triazine-1,5,7-trione (**2a**) as yellow crystals, yield 68%, m.p. 168°C. IR (KBr): 3221 (NH), 1732-1710 (br. C=O), 1635 (C=N), 1588, 1514 (C=C) cm⁻¹. ¹H-NMR (DMSO-d₆):

3.98 (s, 2H, NCH₂CO), 7.13-8.61 (m, 10H, Ar-H and H-olefinic), 12.21-12.23 (br. s, 1H, NH) ppm. 13 C-NMR (DMSO-d₆): 172.34, 170.70, 163.97 (C=O), 147.75, 147.57, 141.16, 140.28, 133.68, 133.47, 133.17, 132.84, 130.92, 130.30, 129.57, 129.44, 129.26, 129.16, 128.81, 128.48, 128.28, 128.08, 124.26, 123.73, 122.03 (C-aromatic and C-triazine), 36.28 (NCH₂CO) ppm. MS (m/z, %) = 392 (M⁺+1, 790), 391 (M⁺, 25.30), 380 (3.20), 379 (4.10), 351 (1.80), 350 (4.90), 336 (3.30), 335 (3.80), 334 (7.70), 321 (2.30), 320 (3.10), 314 (3.70), 310 (2.40), 309 (16.00), 308 (78.40), 294 (12.60), 293 (54.30), 292 (18.90), 291 (11.60), 277 (5.00), 276 (21.70), 264 (4.40), 263 (5.60), 262 (8.20), 261 (4.20), 248 (5.00), 247 (22.80), 246 (18.80), 236 (3.20), 234 (1.70), 233 (2.60), 232 (2.30), 218 (2.50), 217 (2.60), 216 (2.40), 204 (4.70), 203 (5.60), 202 (8.10), 191 (2.40), 190 (7.60), 189 (3.80), 188 (5.00), 178 (2.30), 177 (2.90), 175 (6.90), 179 (11.00), 163 (5.30), 162 (21.00), 161 (4.50), 152 (2.60), 151 (3.70), 150 (6.70), 148 (14.80), 147 (6.60), 145 (12.00), 136 (2.10), 135 (5.00), 132 (10.70), 131 (30.40), 129 (5.80), 128 (3.70), 120 (10.10), 119 (100), 116 (7.60), 115 (10.80), 111 (4.90), 106 (8.30), 105 (89.50), 104 (89.50), 103 (41.90), 102 (8.60), 101 (14.20), 91 (5.20), 90 (4.20), 89 (16.40), 78 (7.60), 77 (91.40), 76 (21.80), 75 (14.90), 72 (12.60), 69 (8.70), 64 (3.60), 63 (8.30), 57 (10.50), 51 (13.40). Anal. Calcd. for C₁₉H₁₃N₅O₅ (391): C, 58.31; H, 3.32; N, 17.90. Found: C, 58.23; H, 3.16; N, 17.77.

2-(*p*-Nitrobenzylidene)-4-phenyl-thioxo-triazino-[2,1-a]-1,2,4-triazine-1,7-dione (**2b**) as yellow crystals, yield 71%, m.p. 260°C. IR (KBr): 3157 (NH), 1730-1705 (br. C=O), 1637 (C=N), 1595, 1516 (C=C), 1448 (C=S) cm⁻¹. ¹H-NMR (DMSO-d₆): δ 3.94 (s, 2H, NCH₂CO), 7.35-8.59 (m, 10H, Ar-H and H-olefinic), 12.22 (br.s, 1H, NH) ppm. ¹³C-NMR (DMSO-d₆): δ 174.61 (C=S), 168.23, 166.03, 161.85 (C=O), 154.77, 148.62 (C-O), 140.80, 140.06, 139.65, 136.70, 134.75, 133.64, 133.39, 133.31, 129.88, 129.44, 129.36, 128.99, 128.87, 127.98, 127.44, 125.28, 125.18, 124.54, 124.36, 124.24 (C-aromatic, triazine and olefinic), 33.62 (NCH₂CO) ppm. Anal. Calcd. for C₁₉H₁₃N₅O₄S (407): C, 56.02; H, 3.19; N, 17.20. Found: C, 55.98; H, 3.02; N, 17.01.

Synthesis of 2-(*p*-nitrobenzylidene)-4-phenyl-5-substituted-6-(ethoxycarbonyl)methyl-1,2,4-triazino-[2,1-*a*]-1,2,4-triazine-1,7-diones (3a,b)

A mixture of compounds 2a and 2b (0.01 mole) and ethyl chloroacetate (0.01 mole) in dimethyl formamide (30 ml) was heated under reflux for 2-3 hr, then cooled and poured into water. The product formed was filtered off, washed with water, dried and purified by recrystallization from ethanol to give 3a,b.

2-(*p*-Nitrobenzylidene)-4-phenyl-6-(ethoxycarbonyl)methyl-1,2,4-triazino-[2,1-a]-1,2,4-triazine-1,5,7-trione (**3a**) as pale yellow crystals, yield 65%, m.p. 105°C. IR (KBr): 1755, 1735 (C=O), 1635 (C=N), 1595, 1517 (C=C), 1107, 1028 (C-O) cm^{-1.} ¹H-NMR (DMSO-d₆): δ 7.31-8.61 (m, 10 H, Ar-H and H-olefinic), 4.19 (q, 2H, OCH₂), 3.98 (s, 2H, NCH₂CO), 2.50 (s, 2H, NCH₂CO), 1.16 (t, 3H, CH₃) ppm. ¹³C-NMR (DMSO-d₆): δ 170.81, 168.50, 160.85 (C=O), 148.32, 140.29, 137.84, 133.96, 133.52, 133.14, 129.89, 129.34, 129.19, 128.90, 128.47, 128.27, 128.01, 127.45, 127.29, 126.70, 125.92, 124.32, 124.16 (C-aromatic, triazine and C-olefinic), 61.45 (OCH₂), 36.28, 24.96 (2 x NCH₂CO), 14.42 (CH₃) ppm. MS (m/z, %) = 478 (M⁺+1, 7.60), 477 (M⁺, 27.80), 442 (6.60), 441 (22.90), 394 (3.90), 393 (3.90), 392 (11.80), 391 (16.40), 351 (7.20), 350 (29.70), 335 (3.20), 334 (4.60), 333 (3.10), 321 (4.50), 320 (3.80), 319 (4.20), 309 (10.00), 308 (50.30), 294 (14.60), 293 (65.40), 292 (23.70), 291 (15.20), 278 (2.20), 277 (6.10), 276 (27.10), 263 (3.00), 262 (3.10), 261 (3.80), 248 (5.70), 247 (27.40), 246 (24.50), 218 (2.70), 217 (3.00), 163 (4.60), 162 (24.40), 161 (10.30), 149 (14.30), 145 (10.20), 144 (7.90), 132 (10.20), 131 (30.00), 129 (5.10), 128 (3.80), 119 (41.10), 118 (5.70), 117 (7.50), 115 (9.30), 106 (7.50), 105 (97.20), 104 (100), 103 (45.40), 101 (14.80), 91 (3.80), 90 (4.80), 89 (17.30), 88 (6.60), 77 (56.80), 76 (21.10), 75 (14.90), 63 (7.40), 62 (3.20), 51 (9.70). Anal. Calcd for C₂₃H₁₉N₅O₇ (477): C, 57.86; H, 3.98; N, 14.67. Found: C, 57.63; H, 3.76; N, 14.48.

2-(*p*-Nitrobenzylidene)-4-phenyl-5-thioxo-6-(ethoxycarbonyl)methyl-triazino-[2,1-a]-1,2,4-triazine-1,7-dione (**3b**) as pale yellow crystals, yield 71%, m.p. 168°C. IR (KBr): 1760-1707 (br. C=O), 1637 (C=N), 1597, 1516 (C=C), 1446 (C=S), 1107, 1026 (C-O) cm⁻¹. ¹H-NMR (DMSO-d₆): δ 1.13 (t, 3H, CH₃), 2.51 (s, 2H, NCH₂CO), 3.89 (s, 2H, NCH₂CO), 4.23 (q, 2H, OCH₂), 7.23-8.61 (m, 10H, Ar-H and H-olefinic) ppm. ¹³C-NMR (DMSO-d₆): 167.92 (C=S), 166.73, 165.58, 164.69 (C=O), 148.65, 147.51 (C-O), 140.79, 139.63, 133.72, 133.62, 133.46, 133.29, 132.63, 132.09, 131.27, 131.00, 129.84, 129.64, 129.43, 129.21, 128.95, 128.65, 128.32, 127.97, 125.21, 124.53, 124.21, 124.06, 123.83 (C-aromatic, triazine and C-olefinic), 62.02 (OCH₂), 39.35 (NCH₂CO), 33.62 (NCH₂CO), 14.46 (CH₃) ppm. Anal. Calcd for C₂₃H₁₉N₅O₆S (493): C, 55.98; H, 3.85; N, 14.20. Found: C, 55.71; H, 3.63; N, 14.02.

Synthesis of 8-arylidene-5-thioxo-4-phenyl-2-(*p*-nitrobenzylidene)-1,2,4-triazino-[2,1-*a*]-1,2,4-triazine-1,7-diones (4a,b)

A mixture of **2b** (0.01 mole), aromatic aldehydes (such as benzaldehyde and anisaldehyde, 0.01 mole) and piperidine (1 ml) was fused on a hot plate at 120-130°C for 2 hr. The reaction mixture was dissolved in ethanol and acidified with dilute hydrochloric acid (2N). The crude product obtained was filtered off, washed with water, dried and purified by recrystallization with acetic acid to give **4a**,**b**.

8-Benzylidene-5-thioxo-4-phenyl-2-(p-nitrobenzylidene)-1,2,4-triazino-[2,1-a]-1,2,4-triazine-1,7-dione (4a) as yellow crystals, yield 74%, m.p. 270°C. IR (KBr): 3210-2650 (br. OH), 1716 (C=O), 1643 (C=N), 1606, 1587 (C=C), 1446 (C=S), 1107, 1065 (C-O) cm⁻¹. ¹H-NMR (DMSO-d₆): δ 7.33-8.66 (m, 15H, Ar-H and H-olefinic), 12.78 (br. s, 1H, OH) ppm. ¹³C-NMR (DMSO-d₆): δ 167.76 (C=S), 165.12, 162.10 (C=O), 156.37 (C-O), 148.92, 148.68 (C=N), 140.80, 140.38, 136.31, 133.93, 133.70, 131.50, 130.55, 130.45, 130.39, 130.20, 129.75, 129.64, 129.38, 129.02, 128.98, 128.70, 128.45, 128.31, 126.18, 124.55, 124.29, 124.09, 123.15 (C-aromatic, triazine and C-olefinic) ppm. Anal. Calcd for C₂₆H₁₇N₅O₄S (495): C, 63.03; H, 3.43; N, 14.14. Found: C, 62.98; H, 3.31; N, 14.02.

8-(*p*-Methoxybenzylidene)-5-thioxo-4-phenyl-2-(*p*-nitrobenzylidene)-1,2,4-triazino-[2,1-a]-1,2,4-triazine-1,7-dione (**4b**) as yellow crystals, yield 71%, m.p. 285°C. IR (KBr): 3107 (NH), 3200-2597 (br. OH), 1712 (C=O), 1643 (C=N), 1593, 1570 (C=C), 1463 (C=S), 1022, 1008 (C-O) cm⁻¹. ¹H-NMR (DMSO-d₆): δ 3.85 (s, 3H, OCH₃), 7.01-8.71 (m, 15H, Ar-H and H-olefinic), 9.913 (br. s, 1H, NH), 12.51 (br. s, 1H, OH) ppm. ¹³C-NMR (DMSO-d₆): δ 168.30 (C=S), 165.10, 161.12 (C=O), 155.30 (C-O), 148.70, 148.52 (C=N), 140.48, 140.27, 136.21, 133.21, 132.41, 132.28, 131.43, 130.15, 130.12, 129.65, 129.53, 129.23, 129.00, 124.56, 124.32, 124.21, 124.01, 115.35, 114.98 (C-aromatic, triazine and C-olefinic), 55.93 (O-CH₃) ppm. Anal. Calcd for $C_{27}H_{19}N_5O_5S$ (525): C, 61.71; H, 3.62; N, 13.33. Found: C, 61.52; H, 3.37; N, 13.17.

Synthesis of 2-(5-phenylthiazol-2-yl)-3-phenyl-5-(p-nitrobenzylidene)-1,2,4-triazine-6-one (5)

A solution of compound **1b** (0.01 mole), phenacyl bromide (0.01 mole) and fused sodium acetate (0.03 mole) in acetic acid (50 ml) was heated under reflux for 4 hr, then cooled and poured into ice-water. The solid formed was filtered off, washed with water, dried and purified from ethanol to give **5** as pale yellow crystals, yield 73%, m.p.

193°C. IR (KBr): 3280 (NH), 1714 (C=O), 1627 (C=N), 1597-1558 (C=C). ¹H-NMR (DMSO-d₆): δ 7.25-8.61 (m, 16H, Ar-H, H-thiazole and H-olefinic), 12.60 (br. s, 1H, NH) ppm. ¹³C-NMR (DMSO-d₆): δ 168.19, 162.75 (C=O), 148.12, 147.57 (C=N), 141.29, 140.59, 139.08, 136.71, 134.93, 134.33, 133.85, 133.39, 129.88, 129.15, 128.87, 128.31, 128.13, 127.50, 126.05, 125.82, 125.28, 124.62, 124.36, 104.95 (C-aromatic, triazine and C-olefinic) ppm. MS (m/z, %) = 468 (M⁺+1, 8.00), 467 (M⁺, 26.20), 336 (2.80), 325 (7.40), 324 (34.80), 310 (2.90), 309 (9.10), 308 (8.50), 294 (16.20), 293 (77.00), 292 (14.50), 279 (3.10), 278 (8.50), 277 (3.60), 263 (7.10), 262 (4.50), 248 (2.20), 247 (4.40), 246 (3.70), 204 (2.00), 203 (3.00), 202 (6.30), 190 (2.50), 189 (2.90), 177 (13.00), 176 (100), 175 (19.90), 174 (10.20), 163 (2.40), 162 (10.00), 161 (5.30), 149 (6.10), 148 (16.60), 147 (4.60), 135 (11.90), 139 (90.70), 129 (7.50), 121 (8.40), 119 (4.30), 117 (3.40), 116 (5.20), 105 (31.00), 104 (85.50), 103 (19.10), 102 (16.00), 91 (4.60), 90 (11.00), 89 (19.00), 77 (37.70), 76 (15.20), 75 (8.40), 63 (7.70), 62 (3.40), 51 (10.90). Anal. Calcd for C₂₅H₁₇N₅O₃S (467): C, 64.24; H, 3.64; N, 14.94. Found: C, 64.03; H, 3.48; N, 14.77.

Synthesis of 1-acetyl-2-(5-phenylthiazol-2-yl)-3-phenyl-5-(p-nitrobenzylidene)-1,2,4-triazine-6-one (6)

A solution of **5** (0.01 mole) in acetic anhydride (25 ml) was heated under reflux for 2 hr, then cooled and poured into ice-water. The resulting solid was filtered off, washed with water, dried and purified by benzene to give **6** as pale yellow crystals, yield 61%, m.p. 165°C. IR (KBr): 1747, 1708 (C=O), 1643 (C=N), 1597, 1558 (C=C), 1444 (C=S), 1106, 1072 (C-O) cm⁻¹. ¹H-NMR (DMSO-d₆): δ 2.50 (s, 3H, COCH₃), 7.23-8.66 (m, 16H, Ar-H, H-thiazole and olefinic) ppm. ¹³C-NMR (DMSO-d₆): δ 168.20, 161.51 (C=O), 148.39, 147.56 (C=N), 140.24, 139.08, 137.95, 134.44, 134.03, 133.66, 131.15, 130.31, 129.81, 129.40, 129.02, 128.78, 128.58, 128.20, 128.13, 127.41, 127.22, 126.01, 125.76, 124.61, 124.15, 104.94 (C-aromatic, triazine, C-thiazole and olefinic), 21.56 (COCH₃) ppm. MS (m/z, %) = 510 (M⁺+1, 3.50), 509 (M⁺, 9.00), 468 (24.00), 467 (77.20), 439 (2.20), 406 (1.10), 391 (1.30), 361 (1.00), 345 (1.30), 324 (3.40), 310 (2.00), 309 (4.20), 308 (4.00), 294 (14.10), 293 (57.20), 279 (3.00), 278 (11.20), 277 (4.90), 276 (3.30), 264 (1.40), 263 (3.50), 262 (3.00), 247 (4.10), 246 (4.00), 219 (2.10), 218 (7.00), 203 (3.60), 202 (3.60), 201 (2.10), 190 (3.10), 189 (2.50), 177 (7.00), 176 (37.30), 175 (23.70), 179 (16.10), 162 (7.60), 161 (2.90), 149 (5.70), 148 (23.70), 147 (9.30), 135 (16.90), 134 (57.90), 133 (9.00), 129 (14.70), 121 (7.10), 120 (3.40), 119 (3.40), 117 (3.90), 116 (6.90), 115 (7.90), 105 (57.50), 104 (100), 103 (37.60), 102 (21.60), 90 (10.40), 89 (21.80), 88 (9.50), 78 (6.60), 77 (62.50), 76 (27.40), 75 (16.80), 64 (5.40), 63 (13.80), 62 (8.40), 51 (26.00), 50 (17.20). Anal. Calcd for C₂₇H₁₉N₅O₄S (467): C, 63.65; H, 3.73; N, 13.75. Found: C, 63.36; H, 3.56; N, 13.48.

RESULTS AND DISCUSSION

II-1) Chemistry

The 5-(*p*-Nitrobenzylidene)-3-phenyl-2-(aminocarbonyl) or (aminothiocarbonyl)-1,2,4-triazine-6-ones (**1a,b**) were prepared by cyclocondensation of the corresponding 5-(*p*-nitrobenzylidene)-2-phenyl-3,1-oxazol-4-one with semicarbazide hydrochloride and thiosemicarbazide in glacial acetic acid. The 2-substituted 1,2,4-triazine-6-ones (**1a,b**) were converted into the target 2-(*p*-nitrobenzylidene)-4-phenyl-5-oxo(thioxo)-1,2,4-triazino[2,1-*a*]-1,2,4-triazine-1,7-diones (**2a,b**) by the reaction with ethyl chloroacetate in the presence of fused sodium acetate and glacial acetic acid.

Alkylation of triazino-[2,1-a]-1,2,4-triazine-1,7-dione derivatives (**2a,b**) with ethyl chloroacetate in dimethyl formamide under reflux afforded the corresponding 2-(*p*nitrobenzylidene)-4-phenyl-5-oxo(thioxo)-6-(ethoxycarbonyl)methyl-1,2,4-triazino-[2,1-a]-1,2,4-triazine-1,7-diones (**3a,b**).

Condensation of triazino-[2,1-a]-1,2,4-triazine-1,7-dione derivative (**2a**) with aromatic aldehydes (such as benzaldehyde and anisaldehyde) in presence of piperidine under fusion yielded the corresponding 8-arylidene-5-thioxo-4-phenyl-2-(*p*-nitrobenzylidene)-1,2,4-triazino-[2,1-a]-1,2,4-triazine-1,7-diones (**4a,b**). The structures of newly synthesized compounds (**Scheme 1**) were confirmed on the basis of their IR, NMR spectroscopic and EIMS spectrometry analysis as well as elemental analytical data.

The new compounds were synthesized by the general method in **scheme 2**, starting from 5-(*p*-nitrobenzylidene)-3-phenyl-2-(aminothiocarbonyl)-1,2,4-triazine-6-one (**1b**) that was converted into the corresponding 2-(5-phenylthiazol-2-yl)-3-phenyl-5-(*p*-nitrobenzylidene)-1,2,4-triazine-6-one (**5**) using phenacyl bromide as a reagent in presence of fused sodium acetate and glacial acetic acid. Treating the thiazolyl derivative (**5**) with acetic anhydride afforded the corresponding 1-acetyl-2-(5-phenylthiazol-2-yl)-3-phenyl-5-(*p*-nitrobenzylidene)-1,2,4-triazine-6-one (**6**).

The structures of newly thiazole derivatives (5 and 6) were supported on the basis of their infrared, nuclear magnetic resonance spectroscopic and electron impact mass spectrometry analysis as well as elemental analytical data.



Scheme 1



II-2) Mass Spectrometry

The mass spectral decomposition mode [21,22] of 1,2,4-triazine heterocycles containing fused triazine and thiazolyl rings have been suggested and investigated.

Compounds 2a and 3a

The mass spectrum of 2-(*p*-nitrobenzylidene)-4-phenyl-1,2,4-triazino-[2,1-*a*]-1,2,4-triazine-1,5,7-trione (**2a**) (**Figure 1**) as example, showed intense molecular ion peak at m/z 391, consistent with molecular formula $C_{19}H_{13}N_5O_5$.

The molecular ion of compound **2a** fragmented to give peak at m/z 350 by losing ketene cation molecule (C₂HO). The loss of isocyanate group (NCO) from the fragment ion of m/z 350 produce the ion of m/z 308, corresponding to the molecular ion of 5-(*p*-nitrobenzylidene)-3-phenyl-1,2,4-triazine-6-one radical cation. The ion of m/z 308 underwent fragmentation and produce ion of m/z 293 by losing NH group. The ion of m/z 293 underwent fragmentation further and involved pathways as illustrated in scheme 3.

The mass spectra of compound **3a** (Figure 2) was fully consistent with assigned structure, intense molecular ion peak was observed. Thus compound **3a** showed an intense molecular ion peak at m/z 477, corresponding to the molecular formula C₂₃H₁₉N₅O₇.

The loss of lactone molecule ($C_4H_6O_2$) from the molecular ion peak of compound **3a** (m/z 477) gave a fragment ion of m/z 391, corresponding to the molecular ion of compound **2a**. The fragment ion of m/z 391 was broken via a pathway in the same fragmentation processes which was observed for compound **2a** (**Scheme 3**). The EIMS of compound **2a** showed a base peak at m/z 119, while the compound **3a** showed a stable fragment at m/z 104.

Compounds 5 and 6

The mass spectra of compound **5** and **6** show relatively weak and strong molecular ions and peaks typical of a cleavage and rearrangement processes type fragmentation. Thus compound **5** and **6** showed an intense molecular ion peaks at m/z 467 and m/z 509, corresponding to the molecular formulas $C_{25}H_{17}N_5O_3S$ and $C_{27}H_{19}N_5O_4S$, respectively.

From the study of the mass spectrum of compound 5 (Figure 3) it was found that the molecular ion for compound 5 at m/z 467 fragmented further and involved two various possible pathways as illustrated in scheme 4.

The molecular ion peak at m/z 467 for compound **5** fragmented to produce ion of m/z 176, corresponding to the 5-phenyl-2-aminothiazole radical cation. The loss of aminonitrile (NH₂CN) from the stable fragment ion of m/z 176 gave the fragment ion of m/z 134, which lost the sulphur atom and acetylene cation to give peaks at m/z 102 and m/z 77, respectively.

Subsequently, the molecular ion of compound 5 at m/z 467 was also found to undergo fragmentation to produce the ion of m/z 293, corresponding to 5-(*p*-nitrobenzylidene)-2-phenyl-imidazolidine-4-one radical cation. The fragment ion of m/z 293 fragmented further and involved two pathways as illustrated in scheme 4.

The molecular ion peak of compound **6** was observed at m/z 509 (**Figure 4**). The loss of ketene molecule (CH₂CO) from the molecular ion peak at m/z 509 gave a strong fragment ion at m/z 467, corresponding to the molecular ion of compound **5**. The fragment ion of m/z 467 broke further via a pathway similar to compound **5** (scheme 4). The EIMS spectrum of compound **5** showed a stable fragment ion at m/z 176, while in case, the compound **6** gave the base peak at m/z 104.



Scheme 3: Main fragmentation pathway of compound 2a and 3a



Scheme 4 Main fragmentation pathway of compound 5 and 6



Figure 1: Mass spectrum of compound 2a



Figure 2: Mass spectrum of compound 3a







Figure 4: Mass spectrum of compound 6

II-3) Cytotoxicity Assay against Hepatocellular Carcinoma Cells

All the newly synthesized fused 1,2,4-triazino-1,2,4-triazine and thiazolyl-1,2,4-triazine derivatives were evaluated for their cytotoxicity against hepatocellular carcinoma cells (HepG-2 cell line) by Mosmann and Vijayan et al assay [23,24]. The 50% inhibitory concentration (IC₅₀) of HepG-2 cell lines was calculated from **table 1**, **Figure 5** and **6**.

Table 1: Evaluation of cytotoxicity of fused triazino-and thiazolyl-1,2,4-triazine derivatives against HepG-2 cell line.

Sample	Viability %										
Concentration (µg)	1 a	1b	2b	3b	4a	4b	5	6	Vinblastine standard		
50	18.74	7.45	10.32	21.65	32.78	10.94	20.38	28.21	7.82		
25	29.16	15.39	17.63	35.16	45.07	18.42	27.06	36.87	15.18		
12.5	41.53	22.76	24.18	60.47	69.42	24.31	38.94	49.76	29.60		
6.25	62.47	31.49	32.94	75.28	81.59	38.53	59.61	72.94	48.75		
3.125	79.41	40.75	45.21	82.44	92.68	53.91	78.24	81.52	60.35		
1.56	88.15	59.27	61.89	90.25	98.73	74.85	86.93	90.63	76.24		

The IC₅₀ values are the concentration that induces 50% growth inhibition compared with untreated control cells.



Figure 5: The inhibitory activities of compounds 1a, b, 2b and 3b



Figure 6: The inhibitory activities of compounds 4a, b, 5 and 6

The results of 50% inhibitory concentration (IC_{50}) data are summarized in Table 2

Table 2: IC₅₀ (µg) values of synthesized compounds after 72 hour continuous exposure of tumour cell lines.

Compound number	1a	1b	2b	3b	4a	4b	5	6	Vinblastine standard
HepG-2 cell line	10.00	2.34	2.67	17.70	22.50	3.92	9.16	12.40	4.60

All the newly synthesized compounds have a cytotoxic effect against hepatocellular carcinoma cells. Compounds **1b**, **2b** and **4b** have a better cytotoxic effect than the corresponding compounds **1a**, **3b**, **4a**, **5** and **6**, comparing with the vinblastine drug assay.

CONCLUSION

The new fused triazino- and thiazolyl-1,2,4-triazine derivatives were synthesized using easy accessible methods, and their structures confirmed by IR, NMR spectroscopic and EIMS spectrometry, and elemental analysis. The synthesized 1,2,4-triazine derivatives have a cytotoxic effect against HepG-2 cell line. Furthermore the 1,2,4-triazine derivatives (**1b,2b** and **4b**) showed good activities than another triazine derivatives against HepG-2 cell line. Some 1,2,4-triazine derivatives were found to play an important role in medical chemistry as antitumor activity.

REFERENCES

[1] Sztanke, K.; Fidecka, S.; Kedzierska, E.; Karczmarzyk, Z.; Pihlaja, K.; Matosiuk, D.; Eur. J. Med. Chem., 2005, 40, 127.

[2] Nyffenegger, C.; Fournet, G.; Joseph, B.; Tetrahedron Lett., 2007, 48, 5069.

[3] Wamhoff, H.; Tzanova, M.; Arkivoc, 2003, (II), 98.

[4] Rees, R. W.; Russel, P. B.; Foell, T. J.; Bright, R. E.; J. Med. Chem., 1972, 15, 859.

[5] Abd EL-Moneim, M.; EL-Deen, I. M.; Abd EL-Fattah, W.; Indian J. Applied Rese., 2013, 3, 106.

[6] Phucho, T.; Nongpiar, A.; Tumtin, S.; Nongrum, R.; Myrboh, B.; Nongkhlaw, R. L.; Arkivoc, 2008, (XV), 74.

[7] EL-Hady, H. A.; EL-Sakka, S. S.; Int. J. Innov. Rese. Science, Engineering and Techn.; 2014, 3, 10854

[8] Kidwai, M.; Goel, Y. and Kumar, R.; Indian J. Chem., 1998, 378, 174

[9] Holla, B. S.; Gonsalves, R.; Rao, B.S.; Shenoy, S. and Gopalakrishna, H.N.; IL Farmaco, 2001, 56, 899.

[10] Abdel-Rahman, R.M.; Morsy, J.M.; Hanafy, F.; Amene, H. A.; Pharmazie, 1999, 54, 347.

[11] Kukla, M. J.; Janssen, P. A. J.; Eur. Pat. 1999, 447, 945.

[12] Burkhard, K.; Gilbert, I. H.; J. Med. Chem.; 2001, 44, 3440.

[13] Partridge, M. W.; Stevens, M. F. G.; J. Chem. Soc., 1966, 1127.

[14] Lino Y.; Morishita Y.; Anticancer Res., 1998, 18, 171.

[15] Abd E. I.; samii, Z. K.; J. Chem. Technol. Biotechnol., 1992, 53, 143.

[16] Anjaneyulu, A. S. R.; Sudharaki, G.; J. Ind. Chemi, 1995, 34(B), 933.

[17] Hay, M. P.; Prujm, F. B.; Gamage, S. A.; Liyanage, H. D.; Wilson, W. R.; J. Med. Chem., 2004, 47, 475.

[18] Heilman, W. P.; Heilman, R. D.; Scozzie, J. A.; Wayner, R. J.; Gullo, J. M.; Ariyan, Z. S.; J. Med. Chem., **1979**, 22, 671.

[19] Erickson, J. G.; Chem. Heterocycl. Comp., 1956, 10, 44.

[20] Jones, R. L.; Kershaw, J. R.; Rev. Pure Appl. Chem., 1971, 21, 23.

[21] EL-Deen, I. M.; Abd EL-Fattah, M. E.; Bull. Korean Chem. Soc., 2003, 24, 473

[22] Mohamed, S. M.; Egypt. J. Chem., 2006, 49, 85.

[23] Mosmann, T.; J. Immunol. Methods, 1983, 55, 65.

[24] Gangadevi, V.; Muthumary, J.; J. African Biotec., 2007, 6, 1382.